The 26 most recent market catalysts affecting $BBIO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 85
BridgeBio Pharma shares are trading lower. The company reported data showing acoramidis reduced the risk of early clinical worsening versus tafamidis in ATTR-CM.
The headline indicates a significant corporate catalyst for BridgeBio Pharma (BBIO). While the clinical data for acoramidis is positive, showing a reduction in early clinical worse…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 85
BridgeBio Says Acoramidis Associated With 34% Lower Risk Of Clinical Worsening vs. Tafamidis In Real-World Study
The headline suggests Acoramidis, BridgeBio's drug, demonstrates significantly better real-world outcomes compared to Tafamidis (Pfizer's Vyndaqel/Vyndamax). This 34% lower risk of…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Beta Bionics shares are trading higher after Baird and Truist Securities raised their respective price targets on the stock.
This headline indicates a strong positive catalyst for Beta Bionics. Analyst upgrades, especially from multiple reputable firms like Baird and Truist, often lead to increased buyin…
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 75
BridgeBio Oncology shares are trading lower after Leerink Partners lowered its price target on the stock from $39 to $27.
This headline indicates a significant negative catalyst for BridgeBio Oncology (BBIO). A price target reduction from a reputable firm like Leerink Partners often reflects concerns …
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating and a $120 price target for BridgeBio Pharma (BBIO). This is a routine a…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 75
BridgeBio Oncology Therapeutics shares are trading lower after the company announced new clinical data for KRASG12C inhibitor BBO-8520.
The headline indicates a direct corporate catalyst for BridgeBio Oncology Therapeutics (BBIO), as new clinical data for their key drug candidate, BBO-8520, has led to a share price…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 85
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain
BridgeBio Pharma announced positive 52-week clinical data for its oral infigratinib in treating achondroplasia, showing benefits in sleep apnea, otitis media, and body composition,…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
BridgeBio's Oral Infigratinib Shows Reduced Sleep Apnea And Ear Infection Rates Beyond Growth Benefits In Phase 3 PROPEL 3 Trial At 52 Weeks
BridgeBio's 8-K filing reveals new, positive exploratory data from its Phase 3 PROPEL 3 trial for oral infigratinib in achondroplasia. Beyond the previously reported growth benefit…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Bridgebio Oncology Therapeutics Says BBO-8520 Monotherapy Shows 63% ORR, 100% DCR In 2L+ KRASG12C NSCLC; BBO-11818 And BBO-10203 Monotherapy Data Update Expected In Q4 2026; Expanded BBO-8520 Plus Pembrolizumab Dataset Expected In Mid-2027; BBO-11818 And BBO-10203 Combination Data In CRC And PDAC Expected Mid-2027
This headline is a major positive catalyst for BridgeBio Pharma (BBIO). The 63% ORR and 100% DCR for BBO-8520 monotherapy in a challenging 2L+ KRASG12C NSCLC population are highly …
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 85
BridgeBio Pharma Announces Late-Breaking Oral Presentation Of Phase 3 PROPEL 3 Data On Oral Infigratinib In Achondroplasia At ESPE 2026 On September 9
The announcement of late-breaking oral presentation of Phase 3 data for infigratinib is a major catalyst for BridgeBio Pharma (BBIO). Positive results would validate their pipeline…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target
This 8-K filing discloses that HC Wainwright & Co. has reiterated its 'Buy' rating and $120 price target for BridgeBio Pharma. This is a routine analyst update, indicating that the…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on BridgeBio Pharma, Raises Price Target to $110
Mizuho analyst Salim Syed maintained an 'Outperform' rating on BridgeBio Pharma and raised the price target from $96 to $110. This action signals increased confidence from a promin…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, BridgeBio Reports New Data Suggesting Attruby Could Help Reverse Some Heart Damage
BridgeBio Pharma announced new, positive data from its Phase 3 ATTRibute-CM study for Attruby (acoramidis), specifically highlighting evidence of reversal in heart damage for patie…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathy
BridgeBio Pharma has dosed the first patient in its ASCEND-ATTR trial, a Phase 3b/4 study for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). This trial aims to furth…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 55
BridgeBio Pharma To Present Two Oral Presentations, Three Posters On New Acoramidis Data In Individuals With Transthyretin Amyloid Cardiomyopathy At European Society Of Cardiology Congress 2026
BridgeBio Pharma is announcing that it will present new data on its drug acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) at a major cardiology conference in August 20…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 65
BridgeBio Pharma Announces Pricing Of 5,000,000-Share Secondary Offering By Selling Stockholder KKR Genetic Disorder; Company Receives No Proceeds
The pricing of a 5,000,000-share secondary offering by a significant stockholder like KKR Genetic Disorder for BridgeBio Pharma (BBIO) is a moderate corporate catalyst. The primary…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 65
BridgeBio Pharma Launches Secondary Public Offering Of 5M Shares Of Common Stock By Selling Stockholder KKR Genetic Disorder L.P
BridgeBio Pharma announced that KKR Genetic Disorder L.P. is selling 5 million shares of BBIO common stock in a secondary public offering. This event is significant because it repr…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $107
Truist Securities analyst Danielle Brill maintained a 'Buy' rating on BridgeBio Pharma (BBIO) and raised the price target from $102 to $107. This action signals continued bullish s…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106
Canaccord Genuity analyst Whitney Ijem maintained a 'Buy' rating on BridgeBio Pharma (BBIO) and raised the price target from $104 to $106. This action signals continued analyst con…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $111
JP Morgan analyst Anupam Rama has maintained an 'Overweight' rating on BridgeBio Pharma and raised the price target from $100 to $111. This action signals a positive outlook from a…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110
TD Cowen analyst Tyler Van Buren has maintained a 'Buy' rating on BridgeBio Pharma (BBIO) and raised the price target from $95 to $110. This analyst action signals a continued posi…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Maintains Overweight on BridgeBio Pharma, Raises Price Target to $115
Piper Sandler analyst Biren Amin maintained an 'Overweight' rating on BridgeBio Pharma (BBIO) and raised the price target from $111 to $115. This action signals continued bullish s…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102
Wells Fargo analyst Derek Archila has maintained an 'Overweight' rating on BridgeBio Pharma (BBIO) and raised the price target from $98 to $102. This action signals continued bulli…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 65
BridgeBio Pharma Files Prospectus Related To Offer And Sale Of Up To 24.6M Common Shares By Selling Stockholders
BridgeBio Pharma filed a prospectus related to the offer and sale of up to 24.6 million common shares by selling stockholders. This is not a primary offering by the company to rais…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 85
BridgeBio Pharma Announces FDA Accepts For Filing Its New Drug Application For Encaleret To Treat Autosomal Dominant Hypocalcemia Type 1
BridgeBio Pharma announced a significant milestone with the FDA's acceptance of its New Drug Application for encaleret, targeting autosomal dominant hypocalcemia type 1 (ADH1). Thi…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a 'Buy' rating on BridgeBio Pharma (BBIO) and raised the price target from $110 to $120. This action signals increased…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.